Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with CancerPurpose:Experimental Design:Results:Conclusions:, Debie, Yana, Van Audenaerde Jonas R. M., Vandamme Timon, Croes Lieselot, Teuwen Laure-Anne, Verbruggen Lise, Vanhoutte Greetje, Marcq Elly, Verheggen Lisa, Le Blon Debbie, et al. , Clinical Cancer Research, Mar-11-2022, Volume 29, Issue 3, (2022)